ALNY – Alnylam Pharmaceuticals, Inc.
ALNY — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
4.33
Margin Of Safety %
53
Put/Call OI Ratio
0.49
EPS Next Q Diff
0.96
EPS Last/This Y
6.56
EPS This/Next Y
3.56
Price
219.15
Target Price
379.1
Analyst Recom
1.6
Performance Q
-25.89
Upside
-5.5%
Beta
0.28
Ticker: ALNY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | ALNY | 287.94 | 0.53 | 0.29 | 32414 |
| 2026-07-14 | ALNY | 282.26 | 0.53 | 0.19 | 33029 |
| 2026-07-15 | ALNY | 279 | 0.52 | 0.82 | 33605 |
| 2026-07-16 | ALNY | 283.13 | 0.51 | 1.14 | 33674 |
| 2026-07-17 | ALNY | 267.46 | 0.51 | 0.99 | 34432 |
| 2026-07-20 | ALNY | 272.61 | 0.51 | 0.16 | 29150 |
| 2026-07-21 | ALNY | 271.25 | 0.51 | 1.01 | 29445 |
| 2026-07-22 | ALNY | 266.49 | 0.51 | 0.12 | 29641 |
| 2026-07-23 | ALNY | 268.73 | 0.51 | 0.86 | 30041 |
| 2026-07-24 | ALNY | 271.77 | 0.52 | 0.92 | 30217 |
| 2026-07-27 | ALNY | 278.45 | 0.51 | 0.07 | 30355 |
| 2026-07-28 | ALNY | 288.55 | 0.51 | 2.37 | 30490 |
| 2026-07-29 | ALNY | 287.36 | 0.53 | 1.36 | 30899 |
| 2026-07-30 | ALNY | 204.86 | 0.55 | 0.52 | 33135 |
| 2026-07-31 | ALNY | 204.52 | 0.49 | 0.97 | 36290 |
| 2026-08-03 | ALNY | 220.36 | 0.48 | 0.42 | 37256 |
| 2026-08-04 | ALNY | 219.46 | 0.48 | 1.75 | 38286 |
| 2026-08-05 | ALNY | 228.73 | 0.49 | 0.65 | 38959 |
| 2026-08-06 | ALNY | 216.1 | 0.50 | 0.35 | 39968 |
| 2026-08-07 | ALNY | 219.95 | 0.49 | 3.19 | 41150 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | ALNY | 288.02 | 563.5 | 513.5 | 9.37 |
| 2026-07-14 | ALNY | 281.52 | 568.2 | 532.5 | 9.37 |
| 2026-07-15 | ALNY | 279.01 | 568.2 | 553.7 | 9.37 |
| 2026-07-16 | ALNY | 283.09 | 569.6 | 585.6 | 9.37 |
| 2026-07-17 | ALNY | 267.42 | 569.6 | 485.1 | 9.37 |
| 2026-07-20 | ALNY | 272.53 | 570.4 | 592.6 | 9.39 |
| 2026-07-21 | ALNY | 271.27 | 572.3 | 557.8 | 9.42 |
| 2026-07-22 | ALNY | 267.02 | 572.3 | 542.0 | 9.42 |
| 2026-07-23 | ALNY | 268.72 | 572.3 | 574.6 | 9.42 |
| 2026-07-24 | ALNY | 271.79 | 572.3 | 581.6 | 9.42 |
| 2026-07-27 | ALNY | 278.41 | 572.0 | 600.5 | 9.42 |
| 2026-07-28 | ALNY | 288.59 | 573.5 | 618.0 | 9.42 |
| 2026-07-29 | ALNY | 287.20 | 573.5 | 559.2 | 9.42 |
| 2026-07-30 | ALNY | 205.38 | 572.3 | 156.7 | 9.42 |
| 2026-07-31 | ALNY | 205.55 | 572.3 | 562.5 | 9.42 |
| 2026-08-03 | ALNY | 220.36 | -23.4 | 432.8 | 9.09 |
| 2026-08-04 | ALNY | 220.36 | -23.4 | 432.8 | 9.09 |
| 2026-08-05 | ALNY | 228.73 | -19.8 | 616.5 | 8.95 |
| 2026-08-06 | ALNY | 216.04 | -19.8 | 445.7 | 8.95 |
| 2026-08-07 | ALNY | 219.15 | -19.8 | 564.5 | 8.95 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | ALNY | -12.23 | -0.12 | 4.36 |
| 2026-07-14 | ALNY | -12.23 | -0.12 | 4.36 |
| 2026-07-15 | ALNY | -9.58 | -0.12 | 4.36 |
| 2026-07-16 | ALNY | -9.58 | -0.12 | 4.36 |
| 2026-07-17 | ALNY | -9.58 | -0.12 | 4.36 |
| 2026-07-20 | ALNY | -9.58 | 1.36 | 4.36 |
| 2026-07-21 | ALNY | -9.58 | 1.36 | 4.36 |
| 2026-07-22 | ALNY | -9.58 | 1.36 | 4.36 |
| 2026-07-23 | ALNY | -9.58 | 1.36 | 4.36 |
| 2026-07-24 | ALNY | -9.58 | 1.36 | 4.36 |
| 2026-07-27 | ALNY | -9.58 | -0.22 | 4.34 |
| 2026-07-28 | ALNY | -9.58 | -0.22 | 4.34 |
| 2026-07-29 | ALNY | -9.58 | -0.22 | 4.34 |
| 2026-07-30 | ALNY | -9.58 | -0.22 | 4.34 |
| 2026-07-31 | ALNY | -9.58 | -0.22 | 4.34 |
| 2026-08-03 | ALNY | -9.56 | -0.40 | 4.33 |
| 2026-08-04 | ALNY | -9.56 | -0.40 | 4.33 |
| 2026-08-05 | ALNY | -9.56 | -0.40 | 4.33 |
| 2026-08-06 | ALNY | -9.56 | -0.40 | 4.33 |
| 2026-08-07 | ALNY | -9.56 | -0.40 | 4.33 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.84
Avg. EPS Est. Current Quarter
2.33
Avg. EPS Est. Next Quarter
2.8
Insider Transactions
-9.56
Institutional Transactions
-0.4
Beta
0.28
Average Sales Estimate Current Quarter
1438
Average Sales Estimate Next Quarter
1575
Fair Value
335.31
Quality Score
95
Growth Score
64
Sentiment Score
33
Actual DrawDown %
55.8
Max Drawdown 5-Year %
-58.2
Target Price
379.1
P/E
37.02
Forward P/E
21.8
PEG
0.29
P/S
6.11
P/B
21.66
P/Free Cash Flow
36.96
EPS
5.92
Average EPS Est. Cur. Y
8.95
EPS Next Y. (Est.)
12.51
Target Price Estimates Raised
Target Price Estimates Lowered
2
Profit Margin
16.82
Relative Volume
1.08
Return on Equity vs Sector %
29.9
Return on Equity vs Industry %
46
EPS 1 7Days Diff
-0.5
EPS 1 30Days Diff
-0.47
EBIT Estimation
564.5
◆
ALNY
Healthcare
$219.29
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
34.2
Range 1M
11%
Sup Dist
5.1%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
190.2%
EPS NY
48.8%
52W%
6.7%
Long-Term Value
Quality companies, undervalued
STRONG
🟢 BUY
+80.3% upside
Upside
+80.3%
Quality
95
MoS
53%
ALNY — P/E HistoricalBiotechnology
Alnylam Pharmaceuticals, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 2500
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
ALNY
Latest News
—
Caricamento notizie per ALNY…
stock quote shares ALNY – Alnylam Pharmaceuticals, Inc. Stock Price stock today
news today ALNY – Alnylam Pharmaceuticals, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALNY – Alnylam Pharmaceuticals, Inc. yahoo finance google finance
stock history ALNY – Alnylam Pharmaceuticals, Inc. invest stock market
stock prices ALNY premarket after hours
ticker ALNY fair value insiders trading